This week in health news, activist investor Engine Capital urges Avantor's board overhaul, China's Ab&B Bio-Tech IPO sees ...

Shares of IO Biotech fell after the company said a cancer vaccine narrowly missed statistical significance on a Phase 3 study's primary endpoint. The stock was down 36%, to $1.15, late Monday ...

Cylembio did not meet its primary endpoint of progression-free survival (PFS), but did demonstrate a trend towards ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...

IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

Denmark-based IO Biotech’s shares traded 51% higher ahead of the morning bell at $2.74 after the company said that Cylembio ...

IO Biotech (IOBT) announced on Monday that its investigational and therapeutic cancer vaccine, Cylembio, in combination with ...

IO Biotech reported its phase 3 trial readout on melanoma immunotherapy. Check out my updated investment thesis on IOBT stock ...

IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

Investing.com -- IO Biotech (NASDAQ: IOBT) stock rose 6.1% after announcing topline results from its pivotal Phase 3 trial of Cylembio, an investigational cancer vaccine, in combination with Merck ...

Engine Capital urges Avantor board changes; China's Ab&B Bio-Tech shares soar; French chlorine factory fire prompts alert; IO ...